YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
The myelodysplastic syndrome market is poised for steady growth, driven by the increasing burden of MDS among the aging population, rising disease awareness, and the growing adoption of innovative therapies across lower- and higher-risk pa…
SOUTH SAN FRANCISCO, Calif., Sept. 2, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's c…
Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026 at 4:30 p.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Raul RodriguezChief Commercial Officer - David SantosChief Financial Officer - Dean SchornoChief Medical Of…
Rigel Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Moby Strategic Transformation and Commercial Execution Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why…
[Stock market activity shows price changes and trading movements in real time] FabrikaCr As the market moves through second-quarter earnings season, investors are paying close attention to small-cap stocks that combine solid profitability…
(RTTNews) - Rigel Pharmaceuticals Inc. (RIGL) announced that Lisa Rojkjaer retired as Chief Medical Officer of the company on July 1, 2026, and Alison Hannah was appointed as the new CMO the same day. Hannah previously served as Chief Medi…
[Growth bar graph] Dougal Waters As U.S. corporate profit margins remain near historic highs, investors are increasingly looking for companies that can translate strong operating performance into sustained earnings growth. Recent data from…
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images Healthcare stocks have remained in focus as investors look for companies that can deliver strong operational growth w…
SOUTH SAN FRANCISCO, Calif., June 16, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the closing of its license agreeme…
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Pfizer (NYSE:PFE) has entered a new alliance with Sarah Cannon Research Institute to accelerate oncology clinical trials and broade…
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Pfizer and its partners have granted Rigel Pharmaceuticals an exclusive license to commercialize VE…
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Rigel Pharmaceuticals Inc.(NASDAQ:RIGL) stock is trading higher on Tuesday as the company is entering an exclusive global licensing agreem…
Rigel Pharmaceuticals has entered an exclusive global license agreement with Arvinas and Pfizer to develop, manufacture and commercialize VEPPANU (vepdegestrant), the first FDA-approved oral PROTAC for adults with ER+/HER2-, ESR1-mutated a…
Arvinas Inc(NASDAQ:ARVN) reported downbeat results for the first quarter on Tuesday. The company posted quarterly losses of 90 cents per share which missed the analyst consensus estimate of losses of 87 cents per share. The company reporte…
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Pfizer (NYSE:PFE) and Arvinas have transferred global development and commercialization rights fo…
Arvinas logo Key Points Interested in Arvinas, Inc.? Here are five stocks we like better. VEPPANU’s FDA approval was the quarter’s biggest milestone, with CEO Randy Teel calling it the first approval of a heterobifunctional PROTAC degrader…
(RTTNews) - Rigel Pharmaceuticals, Inc. (RIGL) on Tuesday said it has entered into a global license agreement with Arvinas, Inc. (ARVN) and Pfizer Inc. (PFE) to develop, manufacture and commercialize beast cancer treatment Veppanu. Veppanu…
VEPPANU has a novel mechanism of action, is the first and only FDA-approved PROTAC and has the potential to become an important new treatment option for adult patients with 2L+ ER+/HER2-, ESR1-mutated mBC Pivotal Phase 3 VERITAC-2 clinical…
Arvinas Inc. – Arvinas and Pfizer to receive $85 million in upfront and transition payments with potential for additional $320 million in development, regulatory, and commercial milestones and tiered royalites on net sales – NEW HAVEN, Con…
On May 8, 2026, CM Management reported selling its entire 200,000-share stake in Centerra Gold(NYSE:CGAU), an estimated $3.56 million trade based on quarterly average pricing. What happened According to a Securities and Exchange Commission…
On May 8, 2026, CM Management disclosed in a U.S. Securities and Exchange Commission (SEC) filing that it sold its entire stake in Preformed Line Products(NASDAQ:PLPC), an estimated $6.39 million trade based on quarterly average pricing. W…
Rigel Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Moby Strategic Execution and Portfolio Evolution Achieved 26% year-over-year net product sales growth in Q1 2026, driven by strong performance in TAVALISSE and REZLIDHIA despite t…
Jim Cramer reviewed Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) while breaking down 16 stocks for a market facing higher energy costs and economic uncertainty. When a caller asked about the stock during the lightning round, Cramer said: Okay…
Madrigal (MDGL) shares ended the last trading session 12.3% higher at $518.76. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 6.2% gain over the…
CytomX Therapeutics(NASDAQ:CTMX), a biotech company that develops conditionally activated biologics for cancer treatment, closed Monday at $6.75, up 44.23%. The stock is jumping after releasing Phase 1 Varseta-M data in metastatic colorect…
CytomX Therapeutics(NASDAQ:CTMX), a biotech company that develops conditionally activated biologics for cancer treatment, closed Monday at $6.75, up 44.23%. The stock is jumping after releasing Phase 1 Varseta-M data in metastatic colorect…
Image source: The Motley Fool. Date Tuesday, March 3, 2026 at 4:30 p.m. ET Call participants Chief Executive Officer — Raul R. Rodriguez Chief Commercial Officer — David A. Santos Chief Medical Officer — Lisa Rojkjaer Chief Financial Offic…
Rigel Pharmaceuticals logo Key Points Commercial momentum: Rigel reported 2025 net product sales of $232 million, up 60% year-over-year, with a record Q4 of $65.4 million (TAVALISSE $45.6M, GAVRETO $10.2M, REZLIDHIA $9.6M) aided by a Medic…
* Rigel Pharmaceuticals press release [https://seekingalpha.com/pr/20422791-rigel-provides-fourth-quarter-and-full-year-2025-financial-results-and-provides-business] (RIGL [https://seekingalpha.com/symbol/RIGL]): Q4 GAAP EPS of $13.54 beat…
Sanofi SNY announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation to Waylirz (rilzabrutinib) for the treatment of IgG4-related disease (IgG4-RD). The drug is not yet approved for this indic…
* Rigel Pharmaceuticals (RIGL [https://seekingalpha.com/symbol/RIGL]) is scheduled to announce Q4 earnings results on Tuesday, March 3rd, after market close. * The consensus EPS Estimate is $1.20 [https://seekingalpha.com/symbol/RIGL/earni…
Xencor (XNCR) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to a loss of $0.62 per share a year ago. These figures are adjusted for non-recurring items. This quarter…
Both Iovance Biotherapeutics IOVA and Rigel Pharmaceuticals RIGL are small-cap companies focused on the successful commercialization of their marketed products. While Iovance is a cancer biotech concentrated on developing immunotherapies,…
Rigel Pharmaceuticals RIGL had an encouraging year in 2025. The company is yet to report its fourth-quarter and full-year 2025 results, but preliminary figures released last month point to another strong finish — driven primarily by the le…
Shares of Rigel Pharmaceuticals RIGL have surged 59% in the past year, significantly outperforming the industry’s 2% growth. The stock has also outperformed the sector and the S&P 500 during the same period, as shown in the chart below. RI…
Amicus Therapeutics FOLD and Rigel Pharmaceuticals RIGL appeal to growth-focused investors as they target rare diseases, where small patient populations can still support strong revenue growth. Amicus is a mid-cap stock compared to Rigel,…